Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.

about

Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials.Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes.

P2860

Q38229263-6890F79F-93E3-4C05-A239-A50F62E17293 Q38881481-4111ECBF-17F2-4244-907C-3EBFD6225062

P2860

Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.

Item

http://www.wikidata.org/entity/Q38161516

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Searching the place of pitavas ...... of patients with dyslipidemia.

@en

type

Item

label

Searching the place of pitavas ...... of patients with dyslipidemia.

@en

prefLabel

Searching the place of pitavas ...... of patients with dyslipidemia.

@en

P1476

Searching the place of pitavas ...... of patients with dyslipidemia.

@en

P2093

Carlos Escobar

http://www.w3.org/2001/XMLSchema#string

José L Zamorano

http://www.w3.org/2001/XMLSchema#string

Vivencio Barrios

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia

Standards of medical care in diabetes--2013

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

[Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study].

Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.

Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

P304

1597-1612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14779072.2013.844546

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24215190

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias

Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.

about

P2860

P2860

Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921